Abstract
<p><strong>Introduction:</strong> For decades, human chorionic gonadotropin (hCG) has been used for final oocyte maturation. It is proven to have highest life birth rate, comparing to gonadotropin releasing hormone (GnRH) agonist, but unfortunately it can increases the risk of developing ovarian hyper stimulation syndrome (OHSS). There is an ongoing debate over the optimal agent that can trigger final oocyte maturation in antagonist protocol, leading to higher IVF success rate without increasing the risk of OHSS.</p><p><strong>Objective:</strong> To compare IVF outcomes in patient using GnRH agonist trigger and hCG for final oocyte maturation.</p><p><strong>Method: </strong>A retrospective review of in vitro fertilization patient at Daya Medika Clinic and Yasmin Clinic.</p><p><strong>Result: </strong>76 women were analyzed consist of 38 women using GnRH agonist and 38 women using hCG. We found no significant differences on biochemical pregnancy rate (24.00% and 20.51%) between two group, but there were significant differences on fertilization rate (67.72% and 61.32%), cleavage rate (95.04% and 88.92%) and blastocyst rate (13.90% and 7.38%). There was one patient developed OHSS in hCG group</p><p><strong>Conclusion: </strong>GnRH agonists can be considered for use as a trigger final oocyte maturation in the antagonist protocol because some IVF outcomes data showed that GnRH agonists triggering were better than hCG without increasing the risk of OHSS</p>
Highlights
Human chorionic gonadotropin has been used for final oocyte maturation
Provision of human chorionic gonadotropin as a trigger oocyte maturation is a method that is done, it has been proven that the luteinizing hormone (LH) has an important role in regulating ovarian function and is important to the process of oocyte maturation, as well as for the process of ovulation.Currently, many clinicians still rely only on the activity of LH in triggering final oocyte maturation process, so if we look at the process of folliculogenesis can be said that a surge of follicle stimulating hormone (FSH), which occurred in mid-cycle is not have any function
After statistical analysis of the relationship between methods of triggering to the fertilization rate, cleavage rate, blastocyst rate and pregnancy rate, its show that no significant differences on biochemical pregnancy rate (24.00% and 20.51%) between two group, but there were significant differences on fertilization rate (67.72% and 61.32%), cleavage rate (95.04% and 88.92%) and blastocyst rate (13.90% and 7.38%)
Summary
Human chorionic gonadotropin (hCG) has been used for final oocyte maturation. There is an ongoing debate over the optimal agent that can trigger final oocyte maturation in antagonist protocol, leading to higher IVF success rate without increasing the risk of OHSS. To compare IVF outcomes in patient using GnRH agonist trigger and hCG for final oocyte maturation. There was one patient developed OHSS in hCG group. GnRH agonists can be considered for use as a trigger final oocyte maturation in the antagonist protocol because some IVF outcomes data showed that GnRH agonists triggering were better than hCG without increasing the risk of OHSS. According to WHO data in 2012, as many as 50-80 million couples of reproductive age around the world have problems in fertility (infertility) and estimated that each year brings 2 million infertile couples [1]. OHSS prevalence ranges from 5% in patients FIV, where one risk
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
